These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19230029)

  • 1. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
    Hauser RA; Lyons KE; McClain T; Carter S; Perlmutter D
    Mov Disord; 2009 May; 24(7):979-83. PubMed ID: 19230029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
    Kieburtz K;
    Mov Disord; 2011 Jan; 26(1):37-44. PubMed ID: 20925067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
    Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R; Koller WC; Trosch RM; Sherry JH;
    J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
    Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.